Method and compositions for inhibiting tumorigenesis

• US 20040072345A1
• Filed: 06/06/2003
• Published: 04/15/2004
• Est. Priority Date: 06/20/1997
• Status: Abandoned Application

• Current Assignee: New York University
• Original Assignee: New York University
• Inventors: Altaba, Ariel Ruiz i., Sanchez, Maria Pilar
• Application Number:
  US10/456,954
• Publication Number:
  US 20040072345A1
• Time in Patent Office: Days
• US Class Current: 435/368
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/41 Hedgehog proteins; Cyclopamine (inhibitor)
• CPC Class Codes: C12N 2506/08 from cells of the nervous system
• CPC Class Codes: G01N 33/5082 Supracellular entities, e.g. tissue, organisms
• CPC Class Codes: G01N 33/5743 of skin, e.g. melanoma

Abstract

The present invention discloses methods of producing neuronal cells from stem cells, particularly from adult brain stem cells. The use of such neuronal cells in the treatment and/or prevention of neurological diseases, conditions and/or injuries is also disclosed. In addition, the present invention provides a novel source of neuronal cells for use as a laboratory tool.

Claims

1. A method of proliferating a mammalian cell from the Central Nervous System (CNS) and its subsequent differentiation to become a neuron comprising culturing the cell in the presence of an agent that stimulates the SHH-GLI pathway.

2. The method of claim 1, wherein the agent is a hedgehog or an active fragment thereof.

3. The method of claim 2, wherein the hedgehog is selected from the group consisting of sonic hedgehog, desert hedgehog and Indian hedgehog.

4. The method of claim 2, wherein the agent is combined with a therapeutically effective amount of a growth factor.

5. The method of claim 4, wherein the growth factor is Epidermal Growth Factor (EGF).

6. The method of claim 1, wherein the mammalian cell is a brain stem cell.

7. The method of claim 6, wherein the brain cell is either an adult, perinatal or post-natal neural stem cell.

8. The method of claim 7, wherein the adult, perinatal or post-natal neural stem cell is a human adult, perinatal or post-natal neural stem cell.

9. The method of claim 6, wherein the brain cell is a mouse subventricular stem cell.

15. A method for treating and/or preventing a neurologic or neurodegenerative disease, disorder or condition in a mammal, comprising transplanting into the brain of the mammal a neuronal cell prepared by the method of claim 1.

16. The method of claim 15, wherein the mammal is a human.

17. The method of claim 15, wherein the neurologic condition is due to an injury.

18. The method of claim 17, wherein the injury is a spinal cord injury.

19. The method of claim 15, wherein the neurologic condition is due to brain damage arising from trauma to the head or stroke.

20. The method of claim 15, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer'"'"'s disease, Huntington'"'"'s disease, Parkinson'"'"'s Disease, schizophrenia, multiple sclerosis, amyotropic lateral sclerosis (ALS), progressive supranuclear palsy, Creutzfeldt-Jakob Disease, epilepsy, and dementia.

22. A method for enhancing the neuronal content of an adult mammalian brain comprising transplanting into the brain of the mammal a neuronal cell prepared by the method of claim 1.

23. A method of delivering or expressing a gene in the CNS or brain of a subject comprising transplantation into the brain of the subject a neuronal cell preparation prepared by the method of claim 1, wherein the neuronal cells have been genetically modified to encode a specific gene.

10. A method of generating a neuron from an adult, perinatal or post-natal neural stem cell comprising culturing the stem cell in the presence of an agent that stimulates the SHH-GLI pathway.

11. The method of claim 10, wherein the agent is a hedgehog or an active fragment thereof.

12. The method of claim 11, wherein the hedgehog is selected from the group consisting of sonic hedgehog, desert hedgehog and Indian hedgehog.

13. The method of claim 11, wherein the agent is combined with a therapeutically effective amount of a growth factor.

14. The method of claim 13, wherein the growth factor is Epidermal Growth Factor (EGF).

21. A method for treating and/or preventing a neurologic or neurodegenerative disease, disorder or condition in a mammal, comprising transplanting into the brain of the mammal an expression vector that encodes sonic hedgehog or an active fragment thereof.

24. A method of treating tumors comprising administering an agent that blocks endogenous SHH and/or GLI signaling.

25. The method of claim 24, wherein said agent is a small interfering RNA molecule comprising sequences derived from Gli 1, Gli 2 or Gli 3.

26. The method of claim 25, comprising the sequences identified in SEQ ID NOs:

15, 16 , 17,

     18).

27. The method of claim 24, wherein said agent is cyclopamine, or an analog or a derivative thereof.

28. A pharmaceutical composition for the treatment of tumors, comprising the agents of any of claims 24 through 27 and a pharmaceutically acceptable carrier.